Sebastian Pomplun studied Chemistry and Pharmaceutical Technologies at the University Sapienza, in Rome. In his doctoral studies in organic and medicinal chemistry at the Max-Planck-Institute of Psychiatry in Munich (supervised by Prof. Felix Hausch) he developed asymmetric synthesis strategies for caged bicylic inhibitors of the psychiatric risk factor protein FKBP51. The resulting PhD thesis was awarded with Summa cum Laude in 2015. Sebastian then joined the Chemistry R&D department of Roche Diagnostics GmbH in Penzberg, Germany, as a postdoctoral research scientist. He developed novel bioconjugation reagents, cleavable linkers for peptides and functional building blocks for nanopore sequencing strategies. In 2019 Sebastian received a postdoctoral fellowship from the German Research Foundation (DFG) and joined the Pentelute Lab at the Massachusetts Institute of Technology in Cambridge, USA. At MIT he worked on rational and combinatorial strategies for the discovery of biohybrid molecules targeting disease related nucleic acids. In September 2021 Sebastian started as a tenure track assistant professor at the Leiden Academic Centre for Drug Research (LACDR) at Leiden University. His research is funded by LACDR, an ERC Starting Grant, NWO open competition funding and by the Oncode Accelerator program. Since 2024 Sebastian is a junior investigator in the Oncode Institute. https://pomplunlab.com/
